Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SINGAPORE, March 16, 2026 (GLOBE NEWSWIRE) -- Orangekloud Technology Inc. (Nasdaq: ORKT) (“Orangekloud” or “the Company”), a Singapore-based technology company offering the eMOBIQ® No-Code platform...
-
DUBAI, United Arab Emirates, March 16, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance is a lending and borrowing protocol currently operating on the Ethereum Sepolia testnet. According to project...
-
New York, March 16, 2026 (GLOBE NEWSWIRE) -- NEW YORK (March 16, 2026) — The Brain & Behavior Research Foundation (BBRF) today announced it will award $1 million in Distinguished Investigator...
-
Recursion OS clinical trial Jensen Huang, NVIDIA’s (NASDAQ:NVDA) CEO, is now pointing to digital biology to be the next technological wave
-
香港及纽约, March 16, 2026 (GLOBE NEWSWIRE) -- 金电科技有限公司（Nasdaq：KMRK）（「金电科技」或「本公司」）今日宣布其子公司已与专注于开发井口天然气发电方案的能源公司Aurora AZ Energy Ltd.（「Aurora」）成立合资企业，共同在加拿大艾伯塔省（Alberta）建设大型加密货币挖矿、人工智能（AI）及高性能计算（HPC）基础设施。...
-
香港及紐約, March 16, 2026 (GLOBE NEWSWIRE) -- 金電科技有限公司（Nasdaq：KMRK）（「金電科技」或「本公司」）今日宣佈其子公司已與專注開發井口天然氣發電方案的能源公司 Aurora AZ Energy Ltd.（「Aurora」）成立合資企業，攜手於加拿大亞伯達省（Alberta）建設大型加密貨幣挖礦、人工智能（AI）及高性能運算（HPC）基礎設施。...
-
HONG KONG and NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- K‑Tech Solutions Company Limited (Nasdaq: KMRK) (“K‑Tech” or the “Company”), a technology firm specializing in high-performance computing...
-
FARMINGTON, Conn. and CHICAGO, March 16, 2026 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (“HRZN”; NASDAQ: HRZN) announced today that its shareholders, at a special meeting held on...
-
2025 Revenue up 7% Year-Over-Year to $614.9 Million 2025 Net Income of $5.1 Million vs. $7.8 Million in 2024 2025 Gross Profit up 30% Year-Over-Year to $105.6 Million 2025 Adjusted...
-
Elevara Medicines announces dosing of the first patient in its Phase 2b START-SYNERGY clinical trial evaluating ELV001, a novel oral CDK4/6 inhibitor.